Cargando…

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin

BACKGROUND: Acquiring clinically annotated, spatially stratified tissue samples from human glioblastoma (GBM) is compromised by haemorrhage, brain shift and subjective identification of ‘normal’ brain. We tested the use of 5-aminolevulinic acid (5-ALA) fluorescence to objective tissue sampling and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piccirillo, S G M, Dietz, S, Madhu, B, Griffiths, J, Price, S J, Collins, V P, Watts, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405212/ https://www.ncbi.nlm.nih.gov/pubmed/22722315 http://dx.doi.org/10.1038/bjc.2012.271

Ejemplares similares

Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models
por: Jarzabek, M A, et al.
Publicado: (2014)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma
por: Zhang, Wenyan, et al.
Publicado: (2018)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy
por: Castano, A P, et al.
Publicado: (2006)

Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response
por: Ivarsson, K, et al.
Publicado: (2005)

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
por: Koti, M, et al.
Publicado: (2015)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines
por: Lindner, D, et al.
Publicado: (2009)

Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore
por: Zhang, H, et al.
Publicado: (2009)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Using macrophage activation to augment immunotherapy of established tumours
por: Fridlender, Z G, et al.
Publicado: (2013)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics
por: Boult, J K R, et al.
Publicado: (2012)

Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
por: Girard, E, et al.
Publicado: (2012)

Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
por: Lammers, T, et al.
Publicado: (2008)

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression
por: Korbelik, M, et al.
Publicado: (2007)

Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas
por: Separovic, D, et al.
Publicado: (2009)

Immunisation with ‘naïve’ syngeneic dendritic cells protects mice from tumour challenge
por: Grimshaw, M J, et al.
Publicado: (2008)

Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy
por: Dudek, A Z, et al.
Publicado: (2007)

PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer
por: Su, Y, et al.
Publicado: (2010)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
por: Pires, I M, et al.
Publicado: (2012)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy
por: Pirovano, Giacomo, et al.
Publicado: (2017)

Sigma-2 ligands induce tumour cell death by multiple signalling pathways
por: Zeng, C, et al.
Publicado: (2012)

A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
por: Mellor, H R, et al.
Publicado: (2005)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007)

Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy
por: Golding, J P, et al.
Publicado: (2013)

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats
por: Walters, M J, et al.
Publicado: (2014)

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
por: Hardee, M E, et al.
Publicado: (2005)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens
por: Steele, J C, et al.
Publicado: (2006)

Soluble tumour necrosis factor receptor type II and survival in colorectal cancer
por: Babic, Ana, et al.
Publicado: (2016)

The endothelin B (ET(B)) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification
por: Cemazar, M, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_vtpcrc9sdrnt0odvn92mq8edju